Review ArticleClinical Review

Long-Term Therapy to Prevent Stroke

Howard S. Kirshner, José Biller and Alfred S. Callahan
The Journal of the American Board of Family Practice November 2005, 18 (6) 528-540; DOI: https://doi.org/10.3122/jabfm.18.6.528

References

  1. ↵
    American Heart Association. Heart disease and stroke statistic—2004 update. Report available online at: http://www.americanheart.org/downloadable/heart/1079736729696HDSStats2004UpdateREV3–19-04.pdf. 2004.
  2. ↵
    Rosenberg C, Popelka GM. Post-stroke rehabilitation. A review of guidelines for patient management. Geriatrics 2000; 55: 75–81.
  3. ↵
    Spagnoli LG, Mauriello A, Sangiorgi G, et al. Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA 2004; 292: 1845–52.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002; 33: 901–6.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyramidole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year survival after first stroke in the Perth community stroke study. Stroke 2003; 34: 1842–6.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Gorelick PB. Stroke prevention. Arch Neurol 1995; 52: 347–55.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Volpato S, Maraldi C, Blé A, et al. Prescription on antithrombotic therapy in older patients hospitalised for transient ischemic attack and ischemic stroke: the GIFA study. Stroke 2004; 35: 913–7.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Holloway RG, Benesch C, Rush SR. Stroke prevention: narrowing the evidence-practice gap. Neurology 2000; 54: 1899–906.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Arora S, Broderick SP, Frankel M, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke 2005; 36: 1232–40.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Ovbiagele B, Saver JL, Fredieu A, et al. PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology 2004; 63: 1217–22.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381–6.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999; 47: 1255–6.
    OpenUrlPubMedWeb of Science
  15. ↵
    Adams RJ, Chimowitz MI, Alpert JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke 2003; 34: 2310–22.
    OpenUrlFREE Full Text
  16. ↵
    Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901–6.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–9.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Di Napoli M, Papa F, and Bocola V. C-Reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32: 917–24.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Marquardt L, Ruf A, Mansmann U, et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570–4.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Lees KR, Bath PMW, Naylor AR. Secondary prevention of transient ischemic attack and stroke. BMJ 2000; 320: 991–4.
    OpenUrlFREE Full Text
  21. ↵
    Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke. A statement for healthcare professionals from the stroke council of the American Heart Association. Circulation 2001; 103: 163–82.
    OpenUrlFREE Full Text
  22. ↵
    Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129–35.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–304.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004; 17: 59–67.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 2002; 106: 388–91.
  26. ↵
    Kirshner HS. Medical prevention of stroke. South Med J 2003; 96: 354–8.
    OpenUrlCrossRefPubMed
  27. Ezekowitz JA, Straus SE, Majumdar SR, et al. Stroke: strategies for primary prevention. Am Fam Physician 2003; 68: 2379–86.
    OpenUrlPubMedWeb of Science
  28. ↵
    Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl 3): 483S–512S.
  29. ↵
    Hanley D, Gorelick PB, Elliot WJ, et al. Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: a guideline for primary care physicians from the National Stroke Association Work Group on Recurrent Stroke Prevention. J Stroke Cerebrovasc Dis 2004; 13: 196–207.
    OpenUrlPubMed
  30. ↵
    Strauss S, Majumdar SR, McAlister FA. New evidence for stroke prevention. JAMA 2002; 288: 1388–95.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997; 28: 2557–62.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    Schrader J, Lüders S, Kulschewski A, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699–703.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981–97.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    Wright JT, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and non-black patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293: 1595–608.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    AHA/ASA. Statins after ischemic stroke and transient ischemic attack: an advisory statement from the Stroke Council, American Heart Association and American Stroke Association. Stroke 2002; 35: 1023.
    OpenUrl
  40. ↵
    . Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757–67.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    The SPARCL Investigators. Design of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Proceedings of the Ongoing Clinical Trials Session, 28th International Stroke Conference. 2003. Phoenix, Arizona.
  44. ↵
    Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–57.
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack of minor stroke. Lancet 1993; 342: 1255–62.
    OpenUrlPubMedWeb of Science
  46. ↵
    Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691–8.
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. A randomized trial. JAMA 2005; 293: 690–8.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    SPIRIT. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997; 42: 857–65.
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–51.
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576–84.
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625–31.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305–16.
    OpenUrlCrossRefPubMedWeb of Science
  53. ↵
    Homma S, Di Tullio MR, Sciacca RR, et al. Effect of aspirin and warfarin therapy in stroke patients with valvular strands. Stroke 2004; 35: 1436–42.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Alberts MJ, Atkinson R. Risk reduction strategies in ischemic stroke. The role of antiplatelet therapy. Clin Drug Invest 2004; 24: 245–54.
    OpenUrl
  55. ↵
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Weisman SM, Graham D. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162: 2197–202.
    OpenUrlCrossRefPubMedWeb of Science
  57. ↵
    Sacco RL, Sivenius J, Diener H-C. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol 2005; 62: 403–8.
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625–8.
    OpenUrlCrossRefPubMedWeb of Science
  59. ↵
    Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001; 103: 363–8.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Ringleb PA, Bhatt DL, Hirsch AT, et al. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004; 35: 528–32.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–7.
    OpenUrlCrossRefPubMedWeb of Science
  62. ↵
    Amarenco P, Donnan GA. Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin? Stroke 2004; 35: 2606–8.
    OpenUrlFREE Full Text
  63. ↵
    Markus HS, Ringelstein EB, for the CARESS Investigators. The effect of dual antiplatelet therapy compared with aspirin on asymptomatic embolisation in carotid stenosis: the CARESS trial. Cerebrovasc Dis 2004; 17(Suppl 5): 39.
    OpenUrl
  64. ↵
    The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.
    OpenUrlCrossRefPubMedWeb of Science
  65. ↵
    Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15–9.
    OpenUrlAbstract/FREE Full Text
  66. ↵
    Majhail NS, Lichtin AE. Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality. Cleve Clin J Med 2003; 70: 466–70.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    Peters RJG, Mehta SR, Fox KAA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes. Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study. Circulation 2003; 108: 1682–7.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    Steinhubl SR, Berger PB, Mann JT, 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411–20.
    OpenUrlCrossRefPubMedWeb of Science
  69. ↵
    North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325: 445–53.
    OpenUrlCrossRefPubMedWeb of Science
  70. Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA 1991; 266: 3289–94.
    OpenUrlCrossRefPubMedWeb of Science
  71. ↵
    European Carotid Surgery Trialists’ Collaborative Group. Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC European Carotid Surgery Trial. Lancet 1991; 337: 1591–3.
    OpenUrl
  72. ↵
    Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421–8.
    OpenUrlCrossRefPubMedWeb of Science
  73. ↵
    MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomized controlled trial. Lancet 2004; 363: 1491–502.
    OpenUrlCrossRefPubMedWeb of Science
  74. ↵
    Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004; 351: 1493–501.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section